Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

From the transcript:

Helen I. Torley, Halozyme Therapeutics, Inc. - President, CEO & Director [5]

--------------------------------------------------------------------------------

Thank you, Laurie. As I mentioned earlier, we're off to a strong start for 2019, having accomplished multiple key milestones in the first quarter. In the remainder of 2019, we expect multiple additional events and milestones. For our ENHANZE pillar, these include potential regulatory filings for the subcutaneous formulation of Janssen's blockbuster, multiple myeloma drug DARZALEX, in the second half of 2019; potential advancement of a new product candidate into Phase 3; and of course, while we can never predict the timing, we are aggressively pursuing additional collaborations. And for our oncology pillar, we continue to expect top line data for our HALO-301 pivotal Phase 3 study in the second half of 2019.